Platelets

Lancet

Volumn 355, Issue 9214, 2000, Pages 1531-1539

  George, James N ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; COTRIMOXAZOLE; FIBRINOGEN RECEPTOR; GLYCOPROTEIN; QUINIDINE; QUININE; RIFAMPICIN; THROMBOCYTE SLOWING FACTOR; THROMBOPOIETIN;

BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CYTOPLASM; HEMOSTASIS; HUMAN; MEGAKARYOCYTE; PETECHIA; PRIORITY JOURNAL; REVIEW; SUBENDOTHELIUM; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0034728866     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02175-9     Document Type: Review

References (51)

1. Behnke O., Forer A. From megakaryocytes to platelets. platelet morphogenesis takes place in the bloodstream Eur J Haematol. 60:1998;3-23.
2. Kaushansky K. Thrombopoietin. the primary regulator of platelet production Blood. 86:1995;419-431.
3. Gurney A.L., Carver-Moore K., De Sauvage F.J., Moore M.W. Thrombocytopenia in c-mpl-deficient mice. Science. 265:1994;1445-1447.
4. Ihara K., Ishii E., Eguchi M.et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA. 96:1999;3132-3136.
5. Shiozaki H., Miyawaki S., Kuwaki T., Hagiwara T., Kato T., Miyazaki H. Autoantibodies neutralizing thrombopoietin in a patient with megakaryocytic thrombocytopenic purpura. Blood. 95:2000;2187-2188.
6. George J.N. Platelet immunoglobulin G. its significance for the evaluation of thrombocytopenia and for understanding the origin of alpha-granule proteins Blood. 76:1990;859.
7. Shattil S.J., Kashiwagi H., Pampori N. Integrin signaling. the platelet paradigm Blood. 91:1998;2645-2657.
8. Santoro S.A., Zutter M.M. The alpha2beta1 integrin. a collagen receptor on platelets and other cells Thromb Haemost. 74:1995;813-821.
9. Santoso S., Kunicki T.J., Kroll H., Haberbosch W., Gardemann A. Association of the platelet glycoprotein Ia C807 T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood. 93:1999;2449-2453.
10. Lopez J.A., Andrews R.K., Afshar-Kharghan V., Berndt M.C. Bernard-Soulier syndrome. Blood. 91:1998;4397-4418.
11. Kaneshiro M.M., Mielke C.H. Jr., Kasper C.K., Rapaport S.I. Bleeding time after aspirin in disorders of intrinsic clotting. N Engl J Med. 281:1969;1039-1042.
12. Aster R.H. Pooling of platelets in the spleen. role in the pathogenesis of "hypersplenic" thrombocytopenia J Clin Invest. 45:1966;645-657.
13. George J.N., Caen J.P., Nurden A.T. Glanzmann's thrombasthenia. the spectrum of clinical disease Blood. 75:1990;1383-1395.
14. George J.N., Shattil S.J. The clinical importance of acquired abnormalities of platelet function. N Engl J Med. 324:1991;27-39.
15. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 321:1989;129-135.
16. Fiorin F., Steffan A., Pradella P., Bizzaro N., Potenza R., De Angelis V. IgG platelet antibodies in EDTA-dependent pseudothrombocytopenia bind to platelet membrane glycoprotein IIb. Am J Clin Pathol. 110:1998;178-183.
17. Bizzaro N. EDTA-dependent pseudothrombocytopenia. a clinical and epidemiological study of 112 cases, with 10-year follow-up Am J Hematol. 50:1995;103-109.
18. Najean Y., Lecompte T. Hereditary thrombocytopenias in childhood. Semin Thromb Hemost. 21:1995;294-304.
19. Gentilini G., Curtis B.R., Aster R.H. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood. 92:1998;2359-2365.
20. Burgess J.K., Lopez J.A., Berndt M.C., Dawes I., Chesterman C.N., Chong B.H. Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex. characterization of the epitopes Blood. 92:1998;2366-2373.
21. George J.N., Raskob G.E., Shah S.R.et al. Drug-induced thrombocytopenia. a systematic review of published case reports Ann Intern Med. 129:1998;886-890.
22. Warkentin T.E., Chong B.H., Greinacher A. Heparin-induced thrombocytopenia. toward consensus Thromb Haemost. 79:1998;1-7.
23. George J.N., Woolf S.H., Raskob G.E.et al. Idiopathic thromboctyopenic purpura. a practice guideline developed by explicit methods for the American Society of Hematology Blood. 88:1996;3-40.
24. Frederiksen H., Schmidt K. The incidence of ITP in adults increases with age. Blood. 94:1999;909-913.
25. Bolton-Maggs P.H.B., Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet. 350:1997;620-623.
26. Lilleyman J.S. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol. 105:1999;871-875.
27. Vesely S., Buchanan G.R., George J.N., Raskob G.E., Cohen A. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura. results of a survey of practicing pediatric hematology/oncology specialists Am J Pediatr Hematol Oncol. 22:2000;55-61.
28. Bahner I., Kearns K., Coutinho S., Leonard E.H., Kohn D.B. Infection of human marrow stroma by human immunodeficiency virus-1 (HIV-1) is both required and sufficient for HIV-1-induced hematopoietic suppression in vitro. demonstration by gene modification of primary human stroma Blood. 90:1997;1787-1798.
29. Francois B., Trimoreau F., Vignon P., Fixe P., Praloran V., Gastinne H. Thrombocytopenia in the sepsis syndrome. role of hemophagocytosis and macrophage colony-stimulating factor Am J Med. 103:1997;114-120.
30. Amorosi E.L., Ultmann J.E. Thrombotic thrombocytopenic purpura. report of 16 cases and review of the literature Medicine. 45:1966;139-159.
31. George J.N., Gilcher R.O., Smith J.W., Chandler L., Duvall D., Ellis C. Thrombotic thrombocytopenia purpura-hemolytic uremic syndrome. diagnosis and management J Clin Apheresis. 13:1998;120-125.
32. Rock G.A., Shumak K.H., Buskard N.A.et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 325:1991;393-397.
33. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999; 131: 453-462.
34. Laszik Z., Silva F. Hemolytic-uremic syndrome, thrombotic thrombocytopenia purpura, and systemic sclerosis (systemic scleroderma). Jennett J.C., Olson J.L., Schwartz M.M., Silva F.G. Heptinstall's pathology of the kidney, 5th edn. 1998;1003-1057 Lippincott-Raven, Philadelphia.
35. Gottschall J.L., Neahring B., McFarland J.G., Wu G.-G., Weitekamp L.A., Aster R.H. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome. clinical and serological findings in nine patients and review of literature Am J Hematol. 47:1994;283-289.
36. Bennett C.L., Weinberg P.D., Rozenberg-Ben-Dror K., Yarnold P.R., Kwaan H.C., Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. a review of 60 cases Ann Intern Med. 128:1998;541-544.
37. Dang C.T., Magid M.S., Weksler B., Chadburn A., Laurence J. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood. 93:1999;1264-1270.
38. Furlan M., Robles R., Galbusera M.et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 339:1998;1578-1584.
39. Tsai H.-M., Lian E.C.Y. Antibodies to von-Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 339:1998;1585-1594.
40. Mead P.S., Griffin P.M. Escherichia coli O157:H7. Lancet. 352:1998;1207-1212.
41. Shumak K.H., Rock G.A., Nair R.C. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Ann Intern Med. 122:1995;569-572.
42. Burrows R.F., Kelton J.G. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med. 329:1993;1463-1466.
43. Lescale K.B., Eddleman K.A., Cines D.B.et al. Antiplatelet antibody testing in thrombocytopenic pregnant women. Am J Obstet Gynecol. 174:1996;1014-1018.
44. Valat A.S., Caulier M.T., Devos P.et al. Relationships between severe neonatal thrombocytopenia and maternal characteristics in pregnancies associated with autoimmune thrombocytopenia. Br J Haematol. 103:1998;397-401.
45. Martin J.N. Jr., Files J.C., Blake P.G., Perry K.G.Jr., Morrison J.C., Norman P.H. Postpartum plasma exchange for atypical preeclampsia-eclampsia as HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol. 172 07-1127:1995.
46. Blickstein D., Aviram A., Luboshitz J.et al. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients: clinical presentations. Blood. 90:1997;2768-2771.
47. Cortelazzo S., Finazzi G., Ruggeri M.et al. Hydroxyurea for patients with essential thrombocytopenia and a high risk of thrombosis. N Engl J Med. 332:1995;1132-1136.
48. Ruggeri M., Finazzi G., Tosetto A., Riva S., Rodeghiero F., Barbui T. No treatment for low-risk thrombocythaemia. results from a prospective study Br J Haematol. 103:1998;772-777.
49. Sharis P.J., Cannon C.P., Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 129:1998;394-405.
50. Topol E.J., Byzova T.V., Plow E.F. Platelet GPIIb-IIIa blockers. Lancet. 353:1999;227-231.
51. Berkowitz S.D., Sane D.C., Sigmon K.N.et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol. 32:1998;311-319.